drug: nalmefene
*
- Clinical class: opioid reversal
- Chemical class: synthetic opioid
- Action: opioid antagonist
- DEA schedule: none
- Route of administration: parenteral
- Also: nalmetrene
U.S. Preparations:
- Revex® (Baxter) FDA approved for
treatment of:
4.17.1995 complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids
7.9.2008 production discontinued
International Preparations:
- Arthene®, Cervene®, Fenarc®, Incystene®
*Molecule graphic courtesy of Steve Chapman